Citations (112)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Li Di. (2023) Recent advances in measurement of metabolic clearance, metabolite profile and reaction phenotyping of low clearance compounds. Expert Opinion on Drug Discovery 18:11, pages 1209-1219.
Read now
Read now
Shyam H. Kamble, Abhisheak Sharma, Tamara I. King, Francisco León, Christopher R. McCurdy & Bonnie A. Avery. (2019) Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom). Xenobiotica 49:11, pages 1279-1288.
Read now
Read now
Yannick Parmentier, Corinne Pothier, Nicola Hewitt, Ludwig Vincent, Fabrice Caradec, Jia Liu, Feifei Lin, Marie-Michèle Trancart, Fabrice Guillet, Belkacem Bouaita, Christophe Chesne & Bernard Walther. (2019) Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model. Xenobiotica 49:1, pages 22-35.
Read now
Read now
Li Di. (2017) Reaction phenotyping to assess victim drug-drug interaction risks. Expert Opinion on Drug Discovery 12:11, pages 1105-1115.
Read now
Read now
Atsunori Miyata, Masatoshi Hasegawa, Kenji Hachiuma, Haruyuki Mori, Nobuko Horiuchi, Akiko Mizuno-Yasuhira, Yukihiro Chino, Shigeji Jingu, Soichi Sakai, Yoshishige Samukawa, Yasuhiro Nakai & Jun-ichi Yamaguchi. (2017) Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, in humans. Xenobiotica 47:4, pages 332-345.
Read now
Read now
Ramakrishna Nirogi, Raghava Choudary Palacharla, Venkatesham Uthukam, Arunkumar Manoharan, Surya Rao Srikakolapu, Ilayaraja Kalaikadhiban, Rajesh Kumar Boggavarapu, Ranjith Kumar Ponnamaneni, Devender Reddy Ajjala & Gopinadh Bhyrapuneni. (2015) Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays. Xenobiotica 45:2, pages 95-106.
Read now
Read now
C. Desbans, C. Hilgendorf, M. Lutz, P. Bachellier, T. Zacharias, J. C. Weber, H. Dolgos, L. Richert & A.-L. Ungell. (2014) Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors. Xenobiotica 44:1, pages 17-27.
Read now
Read now
Christopher R. Gibson, Ping Lu, Cheri Maciolek, Christen Wudarski, Zoe Barter, Karen Rowland-Yeo, Mark Stroh, Eseng Lai & Deborah A. Nicoll-Griffith. (2013) Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. Xenobiotica 43:12, pages 1027-1036.
Read now
Read now
Jackie Bloomer, Geo Derimanov, Etienne Dumont, Harma Ellens & Christopher Matheny. (2013)
Optimizing the and clinical assessment of drug interaction risk by understanding co-medications in patient populations
. Expert Opinion on Drug Metabolism & Toxicology 9:6, pages 737-751.
Read now
Read now
Articles from other publishers (103)
Nihan Izat, Jayaprakasam Bolleddula, Armina Abbasi, Lionel Cheruzel, Robert S. Jones, Darren Moss, Fatima Ortega-Muro, Yannick Parmentier, Vincent C. Peterkin, Dan-Dan Tian, Karthik Venkatakrishnan, Michael A. Zientek, Jill Barber, J. Brian Houston, Aleksandra Galetin & Daniel Scotcher. (2023) Challenges and Opportunities for In Vitro–In Vivo Extrapolation of Aldehyde Oxidase-Mediated Clearance: Toward a Roadmap for Quantitative Translation. Drug Metabolism and Disposition 51:12, pages 1591-1606.
Crossref
Crossref
Siva Nageswara Rao Gajula, Sakina Asgar Vora, Amol G. Dikundwar & Rajesh Sonti. 2023. Dosage Forms - Innovation and Future Perspectives. Dosage Forms - Innovation and Future Perspectives.
CARL DAVIS. 2022. Drug Metabolism Handbook. Drug Metabolism Handbook
527
552
.
Angela C. Doran, Woodrow Burchett, Connor Landers, Gabrielle M. Gualtieri, Amanda Balesano, Heather Eng, Alyssa L Dantonio, Theunis C. Goosen & R. Scott Obach. (2022) Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach. Drug Metabolism and Disposition 50:9, pages 1259-1271.
Crossref
Crossref
Poonam Giri, Lakshmikant Gupta, Anil Rathod, Vipul Joshi, Shyamkumar Giri, Nirmal Patel, Sameer Agarwal & Mukul R Jain. (2022) ZY12201: A Potent TGR5 Agonist: Identification of a Novel Pan CYP450
Inhibitor Tool Compound for In-Vitro Assessment. Drug Metabolism and Bioanalysis Letters 15:2, pages 116-132.
Crossref
Crossref
Shujun Fu, Feifei Yu, Zhuohan Hu & Tao Sun. (2022) Metabolism-mediated drug–drug interactions – Study design, data analysis, and implications for in vitro evaluations. Medicine in Drug Discovery 14, pages 100121.
Crossref
Crossref
Bahareh Jafari, Mahmoud Gharbavi, Yasamin Baghdadchi, Hamidreza Kheiri Manjili, Javad Mahmoudi, Iraj Jafari-Anarkoli, Shayan Amiri & Mir-Jamal Hosseini. (2022) Mitigated Oxidative Stress and Cognitive Impairments in Transient Global Ischemia using Niosomal Selegiline-NBP delivery. Behavioural Neurology 2022, pages 1-21.
Crossref
Crossref
Alyssa L. Dantonio, Angela C. Doran & R. Scott Obach. (2022) Intersystem Extrapolation Factors Are Substrate-Dependent for CYP3A4: Impact on Cytochrome P450 Reaction Phenotyping. Drug Metabolism and Disposition 50:3, pages 249-257.
Crossref
Crossref
Sheri Smith, Michael Lyman, Bennett Ma, Donald Tweedie & Karsten Menzel. (2021) Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450. Drug Metabolism and Disposition 49:11, pages 995-1002.
Crossref
Crossref
Jieon Lee, Yuching Yang, Xinyuan Zhang, Jianghong Fan, Manuela Grimstein, Hao Zhu & Yaning Wang. (2021) Usage of In Vitro Metabolism Data for Drug‐Drug Interaction in Physiologically Based Pharmacokinetic Analysis Submissions to the US Food and Drug Administration. The Journal of Clinical Pharmacology 61:6, pages 782-788.
Crossref
Crossref
Jasleen K. Sodhi & Leslie Z. Benet. (2021) Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization. Journal of Medicinal Chemistry 64:7, pages 3546-3559.
Crossref
Crossref
Mathieu Vinken. (2021) Primary hepatocyte cultures for liver disease modeling. Current Opinion in Toxicology 25, pages 1-5.
Crossref
Crossref
John O. Miners, Andrew Rowland, Jonathan J. Novak, Kimberly Lapham & Theunis C. Goosen. (2021) Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping. Pharmacology & Therapeutics 218, pages 107689.
Crossref
Crossref
Yaru Peng, Zeneng Cheng & Feifan Xie. (2021) Evaluation of Pharmacokinetic Drug–Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches. Metabolites 11:2, pages 75.
Crossref
Crossref
Kimberly Lapham, Ernesto Callegari, Julie Cianfrogna, Jian Lin, Mark Niosi, Christine C. Orozco, Raman Sharma & Theunis C. Goosen. (2020) In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes. Drug Metabolism and Disposition 48:12, pages 1350-1363.
Crossref
Crossref
Hugues Chanteux, Maria Rosa, Claude Delatour, Johan Nicolaï, Eric Gillent, Sylvie Dell’Aiera & Anna-Lena Ungell. (2020) Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes. Drug Metabolism and Disposition 48:9, pages 778-787.
Crossref
Crossref
Stefanus J. Steyn & Manthena V. S. Varma. (2020)
Cytochrome-P450-Mediated Drug
–
Drug Interactions of Substrate Drugs: Assessing Clinical Risk Based on Molecular Properties and an Extended Clearance Classification System
. Molecular Pharmaceutics 17:8, pages 3024-3032.
Crossref
Crossref
Tom S. Chan, Young-Sun Scaringella, Klairynne Raymond & Mitchell E. Taub. (2020) Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture. Drug Metabolism and Disposition 48:8, pages 690-697.
Crossref
Crossref
Emi Kimoto, R. Scott Obach & Manthena V.S. Varma. (2020) Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions. Drug Metabolism and Pharmacokinetics 35:1, pages 18-29.
Crossref
Crossref
Ren-Jong Liang, Yin-Ning Shih, Yen-Lun Chen, Wei-Yang Liu, Wan-Ling Yang, Shih-Yu Lee & Hong-Jaan Wang. (2020) A dual system platform for drug metabolism: Nalbuphine as a model compound. European Journal of Pharmaceutical Sciences 141, pages 105093.
Crossref
Crossref
Alexander Hoemme, Holger Barth, Manuel Haschke, Stephan Krähenbühl, Florian Strasser, Claudia Lehner, Alexander von Kameke, Thomas Wälti, Beat Thürlimann, Martin Früh, Christoph Driessen & Markus Joerger. (2019) Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer Chemotherapy and Pharmacology 83:4, pages 763-774.
Crossref
Crossref
Roy J. Vaz, Yi Li, Markus Metz, Donglai Yang, Hong Shen & Mark Munson. (2018) Decreasing the CYP2D6 contribution to metabolism of a CK1ε inhibitor. Bioorganic & Medicinal Chemistry Letters 28:23-24, pages 3681-3684.
Crossref
Crossref
Y. Amy Siu, Ming-Hong Hao, Vaishali Dixit & W. George Lai. (2018) Celecoxib is a substrate of CYP2D6: Impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metabolism and Pharmacokinetics 33:5, pages 219-227.
Crossref
Crossref
Lisa K. Morlock, Sascha Grobe, Kathleen Balke, Stephan Mauersberger, Dominique Böttcher & Uwe T. Bornscheuer. (2018) Protein Engineering of the Progesterone Hydroxylating P450-Monooxygenase CYP17A1 Alters Its Regioselectivity. ChemBioChem 19:18, pages 1954-1958.
Crossref
Crossref
Jun-Hyeng Son, Yoo-Seong Jeong, Jong-Hwa Lee, Min-Soo Kim, Kyeong-Ryoon Lee, Chang-Koo Shim, Young Ho Kim & Suk-Jae Chung. (2018) Identification of metabolites of MDR-1339, an inhibitor of β-amyloid protein aggregation, and kinetic characterization of the major metabolites in rats. Journal of Pharmaceutical and Biomedical Analysis 151, pages 61-70.
Crossref
Crossref
Lisa K. Morlock, Dominique Böttcher & Uwe T. Bornscheuer. (2017) Simultaneous detection of NADPH consumption and H2O2 production using the Ampliflu™ Red assay for screening of P450 activities and uncoupling. Applied Microbiology and Biotechnology 102:2, pages 985-994.
Crossref
Crossref
Ken-ichi Umehara, Felix Huth, Helen Gu, Hilmar Schiller, Tycho Heimbach & Handan He. (2017) Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) – a comparison with the chemical inhibition method. Drug Metabolism and Personalized Therapy 32:4.
Crossref
Crossref
Wei Zhou, Xiaohui Hu & Kin Yip Tam. (2017) Systemic clearance and brain distribution of carbazole-based cyanine compounds as Alzheimer’s disease drug candidates. Scientific Reports 7:1.
Crossref
Crossref
Y. Amy Siu & W. George Lai. (2017) Impact of Probe Substrate Selection on Cytochrome P450 Reaction Phenotyping Using the Relative Activity Factor. Drug Metabolism and Disposition 45:2, pages 183-189.
Crossref
Crossref
Stephen Fowler, Elena Guerini, NaHong Qiu, Yumi Cleary, Neil Parrott, Gerard Greig & Navita L. Mallalieu. (2017) Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non–Michaelis-Menten P450 Kinetics on Fraction Metabolized. Journal of Pharmacology and Experimental Therapeutics 360:1, pages 164-173.
Crossref
Crossref
Nicholas M. Njuguna, Ken-ichi Umehara, Felix Huth, Hilmar Schiller, Kelly Chibale & Gian Camenisch. (2016) Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction. Drug Metabolism and Personalized Therapy 31:4, pages 221-228.
Crossref
Crossref
R. Scott Obach, Amit S. Kalgutkar & Deepak K. Dalvie. 2016. Metabolite Safety in Drug Development. Metabolite Safety in Drug Development
87
110
.
Kathleen M. Knights, David M. Stresser, John O. Miners & Charles L. Crespi. (2016) In Vitro Drug Metabolism Using Liver Microsomes. Current Protocols in Pharmacology 74:1.
Crossref
Crossref
T. Bohnert, A. Patel, I. Templeton, Y. Chen, C. Lu, G. Lai, L. Leung, S. Tse, H. J. Einolf, Y.-H. Wang, M. Sinz, R. Stearns, R. Walsky, W. Geng, S. Sudsakorn, D. Moore, L. He, J. Wahlstrom, J. Keirns, R. Narayanan, D. Lang & X. Yang. (2016) Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions--an Industry Perspective. Drug Metabolism and Disposition 44:8, pages 1399-1423.
Crossref
Crossref
Dany Spaggiari, Youssef Daali & Serge Rudaz. (2016) An extensive cocktail approach for rapid risk assessment of in vitro CYP450 direct reversible inhibition by xenobiotic exposure. Toxicology and Applied Pharmacology 302, pages 41-51.
Crossref
Crossref
William Brian, Larry M Tremaine, Million Arefayene, Ruben de Kanter, Raymond Evers, Yingying Guo, James Kalabus, Wen Lin, Cho-Ming Loi & Guangqing Xiao. (2016) Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG. Pharmacogenomics 17:6, pages 615-631.
Crossref
Crossref
X. Yang, K. Atkinson & L. Di. (2015) Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method. Drug Metabolism and Disposition 44:3, pages 460-465.
Crossref
Crossref
Esra Nurten Cece-Esencan, Fabien Fontaine, Guillem Plasencia, Marieke Teppner, Andreas Brink, Axel Pähler & Ismael Zamora. (2016) Software-aided cytochrome P450 reaction phenotyping and kinetic analysis in early drug discovery. Rapid Communications in Mass Spectrometry 30:2, pages 301-310.
Crossref
Crossref
Li Di & Edward H. Kerns. 2016. Drug-Like Properties. Drug-Like Properties
371
386
.
Haifeng Zhang, Na Gao, Xin Tian, Tingting Liu, Yan Fang, Jun Zhou, Qiang Wen, Binbin Xu, Bing Qi, Jie Gao, Hongmeng Li, Linjing Jia & Hailing Qiao. (2015) Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo. Scientific Reports 5:1.
Crossref
Crossref
Silvia Ussai, Riccardo Petelin, Antonio Giordano, Mario Malinconico, Donatella Cirillo & Francesca Pentimalli. (2015) A pilot study on the impact of known drug-drug interactions in cancer patients. Journal of Experimental & Clinical Cancer Research 34:1.
Crossref
Crossref
Edward J. Kelly & Jenna L. Voellinger. 2015. New Horizons in Predictive Drug Metabolism and Pharmacokinetics. New Horizons in Predictive Drug Metabolism and Pharmacokinetics
177
201
.
Edoardo Saccenti, John van Duynhoven, Doris M. Jacobs, Age K. Smilde & Huub C. J. Hoefsloot. (2015) Strategies for Individual Phenotyping of Linoleic and Arachidonic Acid Metabolism Using an Oral Glucose Tolerance Test. PLOS ONE 10:3, pages e0119856.
Crossref
Crossref
Michael A. Zientek & Kuresh Youdim. (2015) Reaction Phenotyping: Advances in the Experimental Strategies Used to Characterize the Contribution of Drug-Metabolizing Enzymes. Drug Metabolism and Disposition 43:1, pages 163-181.
Crossref
Crossref
Gregory S. Walker, Jonathan N. Bauman, Tim F. Ryder, Evan B. Smith, Douglas K. Spracklin & R. Scott Obach. (2014) Biosynthesis of Drug Metabolites and Quantitation Using NMR Spectroscopy for Use in Pharmacologic and Drug Metabolism Studies. Drug Metabolism and Disposition 42:10, pages 1627-1639.
Crossref
Crossref
Neil R. Hartman, Jinzhe J. Mao, Hongfei Zhou, Michael T. BoyneIIII, Adam M. Wasserman, Kellie Taylor, Judith A. Racoosin, Vikram Patel & Thomas Colatsky. (2014) More methemoglobin is produced by benzocaine treatment than lidocaine treatment in human in vitro systems. Regulatory Toxicology and Pharmacology 70:1, pages 182-188.
Crossref
Crossref
Ru Feng, Xuelin Zhou, Xiang-Shan Tan, Penelope M.Y. Or, Tao Hu, Jie Fu, Jing-Yi Ma, Min Huang, Chi-Yu He, Jian-Gong Shi, Chun-Tao Che, John H.K. Yeung & Yan Wang. (2014) In vitro identification of cytochrome P450 isoforms responsible for the metabolism of 1-hydroxyl-2,3,5-trimethoxy-xanthone purified from Halenia elliptica D. Don. Chemico-Biological Interactions 210, pages 12-19.
Crossref
Crossref
Ronald E. White. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
15
.
Michael H. Court. 2014. Optimization in Drug Discovery. Optimization in Drug Discovery
117
136
.
Tonika Bohnert & Lawrence L. Gan. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
61
.
Patricio Godoy, Nicola J. Hewitt, Ute Albrecht, Melvin E. Andersen, Nariman Ansari, Sudin Bhattacharya, Johannes Georg Bode, Jennifer Bolleyn, Christoph Borner, Jan Böttger, Albert Braeuning, Robert A. Budinsky, Britta Burkhardt, Neil R. Cameron, Giovanni Camussi, Chong-Su Cho, Yun-Jaie Choi, J. Craig Rowlands, Uta Dahmen, Georg Damm, Olaf Dirsch, María Teresa Donato, Jian Dong, Steven Dooley, Dirk Drasdo, Rowena Eakins, Karine Sá Ferreira, Valentina Fonsato, Joanna Fraczek, Rolf Gebhardt, Andrew Gibson, Matthias Glanemann, Chris E. P. Goldring, María José Gómez-Lechón, Geny M. M. Groothuis, Lena Gustavsson, Christelle Guyot, David Hallifax, Seddik Hammad, Adam Hayward, Dieter Häussinger, Claus Hellerbrand, Philip Hewitt, Stefan Hoehme, Hermann-Georg Holzhütter, J. Brian Houston, Jens Hrach, Kiyomi Ito, Hartmut Jaeschke, Verena Keitel, Jens M. Kelm, B. Kevin Park, Claus Kordes, Gerd A. Kullak-Ublick, Edward L. LeCluyse, Peng Lu, Jennifer Luebke-Wheeler, Anna Lutz, Daniel J. Maltman, Madlen Matz-Soja, Patrick McMullen, Irmgard Merfort, Simon Messner, Christoph Meyer, Jessica Mwinyi, Dean J. Naisbitt, Andreas K. Nussler, Peter Olinga, Francesco Pampaloni, Jingbo Pi, Linda Pluta, Stefan A. Przyborski, Anup Ramachandran, Vera Rogiers, Cliff Rowe, Celine Schelcher, Kathrin Schmich, Michael Schwarz, Bijay Singh, Ernst H. K. Stelzer, Bruno Stieger, Regina Stöber, Yuichi Sugiyama, Ciro Tetta, Wolfgang E. Thasler, Tamara Vanhaecke, Mathieu Vinken, Thomas S. Weiss, Agata Widera, Courtney G. Woods, Jinghai James Xu, Kathy M. Yarborough & Jan G. Hengstler. (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Archives of Toxicology 87:8, pages 1315-1530.
Crossref
Crossref
Jonas G. Barlind, Linda K. Buckett, Sharon G. Crosby, Öjvind Davidsson, Hans Emtenäs, Anne Ertan, Ulrik Jurva, Malin Lemurell, Pablo Morentin Gutierrez, Karolina Nilsson, Gavin O’Mahony, Annika U. Petersson, Alma Redzic, Fredrik Wågberg & Zhong-Qing Yuan. (2013) Identification and design of a novel series of MGAT2 inhibitors. Bioorganic & Medicinal Chemistry Letters 23:9, pages 2721-2726.
Crossref
Crossref
Kimberley Lentz, Joseph Raybon & Michael W. Sinz. 2013. Drug Discovery. Drug Discovery
99
139
.
Angela Dudda & Gert Ulrich Kuerzel. 2013. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays
1053
1094
.
Zhengyin Yan & Gary W. Caldwell. 2013. Pharmacogenomics. Pharmacogenomics
251
261
.
Alexander V. LyubimovKarthik Venkatakrishnan. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
62
.
Alexander V. LyubimovBennett Ma & Michael L. Schrag. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
29
.
Alexander V. LyubimovRonald E. White. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
40
.
John A. Davis, Dan A. Rock, Larry C. Wienkers & Josh T. Pearson. (2012) In Vitro Characterization of the Drug-Drug Interaction Potential of Catabolites of Antibody-Maytansinoid Conjugates. Drug Metabolism and Disposition 40:10, pages 1927-1934.
Crossref
Crossref
J.-M. Nicolas, H. Chanteux, M. Rosa, S. Watanabe & A. Stockis. (2012) Effect of Gemfibrozil on the Metabolism of Brivaracetam In Vitro and in Human Subjects. Drug Metabolism and Disposition 40:8, pages 1466-1472.
Crossref
Crossref
Alexander V. LyubimovMichael A. Sinz. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
31
.
Robert L. Walsky, Jonathan N. Bauman, Karine Bourcier, Georgina Giddens, Kimberly Lapham, Andre Negahban, Tim F. Ryder, R. Scott Obach, Ruth Hyland & Theunis C. Goosen. (2012) Optimized Assays for Human UDP-Glucuronosyltransferase (UGT) Activities: Altered Alamethicin Concentration and Utility to Screen for UGT Inhibitors. Drug Metabolism and Disposition 40:5, pages 1051-1065.
Crossref
Crossref
Subrata Deb, Mitali Pandey, Hans Adomat & Emma S. Tomlinson Guns. (2012)
Cytochrome P450 3A-Mediated Microsomal Biotransformation of 1α,25-Dihydroxyvitamin D
3
in Mouse and Human Liver: Drug-Related Induction and Inhibition of Catabolism
. Drug Metabolism and Disposition 40:5, pages 907-918.
Crossref
Crossref
Rajinder Bhardwaj & Gamini Chandrasena. 2012. ADME‐Enabling Technologies in Drug Design and Development. ADME‐Enabling Technologies in Drug Design and Development
15
28
.
Chun Li & Nataraj Kalyanaraman. 2012. ADME‐Enabling Technologies in Drug Design and Development. ADME‐Enabling Technologies in Drug Design and Development
189
212
.
Wenying Jian, Wilson Shou, Richard W. Edom, Naidong Weng & Mingshe Zhu. 2012. Mass Spectrometry Handbook. Mass Spectrometry Handbook
119
169
.
Jonas Boström, Anders Hogner, Antonio Llinàs, Eric Wellner & Alleyn T. Plowright. (2012) Oxadiazoles in Medicinal Chemistry. Journal of Medicinal Chemistry 55:5, pages 1817-1830.
Crossref
Crossref
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
183
207
.
Alexander V. LyubimovShelby Anderson, Debra Luffer‐Atlas & Mary Pat Knadler. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
27
.
Alexander V. LyubimovJames M. MKim. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
28
.
Alexander V. LyubimovTonika Bohnert & Chandra Prakash. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
42
.
Jiachang Gong, Jinping Gan & Ramaswamy A. Iyer. (2012) Identification of the Oxidative and Conjugative Enzymes Involved in the Biotransformation of Brivanib. Drug Metabolism and Disposition 40:1, pages 219-226.
Crossref
Crossref
Natalia A. Petushkova & Andrey V. Lisitsa. 2012. Liver Proteomics. Liver Proteomics
63
82
.
H. K. Crewe, Z. E. Barter, K. Rowland Yeo & A. Rostami‐Hodjegan. (2011) Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter‐system extrapolation factors. Biopharmaceutics & Drug Disposition 32:6, pages 303-318.
Crossref
Crossref
W. Griffith Humphreys. 2011. Mass Spectrometry in Drug Metabolism and Disposition. Mass Spectrometry in Drug Metabolism and Disposition
229
253
.
Wenying Jian, Ming Yao, Bo Wen, Elliott B. Jones & Mingshe Zhu. 2011. Mass Spectrometry in Drug Metabolism and Disposition. Mass Spectrometry in Drug Metabolism and Disposition
483
524
.
Martin E. Dowty, Dean M. Messing, Yurong Lai & Leonid (Leo) Kirkovsky. 2011. ADMET for Medicinal Chemists. ADMET for Medicinal Chemists
145
200
.
Xavier Boulenc & Olivier Barberan. (2011) Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development. Drug Metabolism and Drug Interactions 26:4.
Crossref
Crossref
Xavier Boulenc, Wolfgang Schmider & Olivier Barberan. 2011. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology
133
160
.
J. Matthew Hutzler, Jack Cook & Joseph C. Fleishaker. 2011. Pharmacokinetics in Drug Development. Pharmacokinetics in Drug Development
21
56
.
Karthik Venkatakrishnan, Michael D. Pickard & Lisa L. von Moltke. (2010) A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development. Clinical Pharmacokinetics 49:11, pages 703-727.
Crossref
Crossref
Michael Zientek, Ying Jiang, Kuresh Youdim & R. Scott Obach. (2010) In Vitro-In Vivo Correlation for Intrinsic Clearance for Drugs Metabolized by Human Aldehyde Oxidase. Drug Metabolism and Disposition 38:8, pages 1322-1327.
Crossref
Crossref
Kiyomi Ito & Yuichi Sugiyama. (2010) Use of clearance concepts and modeling techniques in the prediction of metabolic drug–drug interactions. Trends in Pharmacological Sciences 31:8, pages 351-355.
Crossref
Crossref
Carl D. Davis & Umesh M. Hanumegowda. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
68
.
Carl D. Davis & A. David Rodrigues. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
58
.
Michael Sinz, Sean Kim, Stephen Ferguson & Edward LeCluyse. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
31
.
M. T. BARATTA, M. J. ZAYA, J. A. WHITE & C. W. LOCUSON. (2010) Canine CYP2B11 metabolizes and is inhibited by anesthetic agents often co-administered in dogs. Journal of Veterinary Pharmacology and Therapeutics 33:1, pages 50-55.
Crossref
Crossref
J. Brian Houston & Aleksandra Galetin. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
169
215
.
K. Sandy Pang, Raimund M. Peter & A. David Rodrigues. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
701
722
.
Ragini Vuppugalla, Sean Kim, Tatyana Zvyaga, Yong-hae Han, Praveen Balimane, Punit Marathe & A. David Rodrigues. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
585
624
.
R. Scott Obach. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
241
264
.
Tonika Bohnert & Liang‐Shang Gan. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
91
176
.
Yitong Liu, Haiping Hao, Hongguang Xie, Hua Lv, Changxiao Liu & Guangji Wang. (2009) Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. Journal of Pharmaceutical Sciences 98:11, pages 4391-4401.
Crossref
Crossref
Nuggehally R. Srinivas. (2009) Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy — Does structural design, dosing and induction strategies have a role to play?. European Journal of Drug Metabolism and Pharmacokinetics 34:3-4, pages 147-150.
Crossref
Crossref
Ruth Hyland, R. Scott Obach, Chad Stoner, Michael West, Michael R. Wester, Kuresh Youdim & Michael Zientek. 2009. Hit and Lead Profiling. Hit and Lead Profiling
165
196
.
Edward L. Croom, Jeffrey C. Stevens, Ronald N. Hines, Andrew D. Wallace & Ernest Hodgson. (2009) Human hepatic CYP2B6 developmental expression: The impact of age and genotype. Biochemical Pharmacology 78:2, pages 184-190.
Crossref
Crossref
Charles W. Locuson, Brian T. Ethell, Michael Voice, David Lee & Kenneth L. Feenstra. (2009)
Evaluation of
Escherichia coli
Membrane Preparations of Canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with Coexpressed Canine Cytochrome P450 Reductase
. Drug Metabolism and Disposition 37:3, pages 457-461.
Crossref
Crossref
Carl D. Davis & A. David Rodrigues. 2009. Drug Metabolism Handbook. Drug Metabolism Handbook
391
447
.
Michael Sinz, Sean Kim, Stephen Ferguson & Edward Lecluyse. 2009. Drug Metabolism Handbook. Drug Metabolism Handbook
359
389
.
Collette D. Linder, Nicole A. Renaud & J. Matthew Hutzler. (2009) Is 1-Aminobenzotriazole an Appropriate in Vitro Tool as a Nonspecific Cytochrome P450 Inactivator?. Drug Metabolism and Disposition 37:1, pages 10-13.
Crossref
Crossref
Dan A. Rock, Robert S. Foti & Josh T. Pearson. (2008) The Combination of Chemical and Antibody Inhibitors for Superior P450 3A Inhibition in Reaction Phenotyping Studies. Drug Metabolism and Disposition 36:12, pages 2410-2413.
Crossref
Crossref
Shu-Ying Chang, Wenying Li, Sarah C. Traeger, Bei Wang, Donghui Cui, Hongjian Zhang, Bo Wen & A. David Rodrigues. (2008)
Confirmation That Cytochrome P450 2C8 (CYP2C8) Plays a Minor Role in (
S
)-(+)- and (
R
)-(-)-Ibuprofen Hydroxylation in Vitro
. Drug Metabolism and Disposition 36:12, pages 2513-2522.
Crossref
Crossref
Cuyue Tang, Brian A. Carr, Frédéric Poignant, Bennett Ma, Stacey L. Polsky-Fisher, Yuhsin Kuo, Kristie Strong-Basalyga, Alisha Norcross, Karen Richards, Roy Eisenhandler, Edward J. Carlini, Christina Ng Di Marco, Scott D. Kuduk, Nathan X. Yu, Conrad E. Raab, Tom Rushmore, Clay B. Frederick, Mark G. Bock & Thomayant Prueksaritanont. (2008)
CYP2C75-Involved Autoinduction of Metabolism in Rhesus Monkeys of Methyl 3-Chloro-3′-fluoro-4′-{(1
R
)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1′-biphenyl-2-carboxylate (MK-0686), a Bradykinin B
1
Receptor Antagonist
. Journal of Pharmacology and Experimental Therapeutics 325:3, pages 935-946.
Crossref
Crossref